Fig. 1.
The characterization of NAL-SA-MVs. (A) TEM imaging of NAL-SA-MVs. (B) The DLS size distribution diagrams of MVs, SA-MVs, NAL-SA-MVs. (C) The ζ potential distribution of MVs, SA-MVs, NAL-SA-MVs. (D) 7 d stability test of NAL-SA-MVs. (E) The vitro release assay of NAL and SA. (F) The pharmacokinetics of free NAL and NAL-SA-MVs in vivo. (G) The cytotoxicity of blank MVs in VSC4.1 and BV2. (H) Western blotting analysis of protein markers of RAW264.7, RAW264.7 cell membranes, SA-MVs and NAL-SA-MVs. All data represented the mean ± SD (n = 3).